A dose of 30 mg/kg IV once a week for 6 weeks, with or without oral maintenance corticosteroid therapy, has been used. Therapy produced immediate improvement in all patients, however, 66% relapsed 1 year later. NERVOUS SYSTEM DISEASE Ed Friedlander, M.D., Pathologist scalpel_blade@yahoo.com No texting or chat messages, please. Ordinary e-mails are welcome. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE is characterized by the production of unusual antibodies in the blood. The cause(s) of systemic lupus erythematosus is (are) unknown, however, heredity, viruses, ultraviolet light, and drugs all may play some role. Plasmapheresis Page 3 of 13 II. Systemic vasculitis (life threatening rheumatoid, polyateritis nodosa, Wegener’s granulomatosis, microscopic vasculitis) unresponsive to conventional therapy (e.g., high- De la Prensa Médica Extranjera Lupus eritematoso sistémico Mills JA. Tomado de: N Engl J Med 1994; 330(z6):1871-9. El lupus eritematoso sistémico (LES) es definido por sus características clínicas y por la presencia casi invariable de anticuerpos en la sangre dirigidos contra uno o más componentes de los núcleos celulares. Number: 0314. Policy. Note: This note applies to the use or rituximab for rheumatoid arthritis: There are several brands of targeted immune modulators on the market. Systemic manifestations of SLE included renal disease in 12 of 14 of the cerebritis group versus 9 of 20 in the noncerebritis group (p 0.05), and systemic vasculitis in 6 of 14 with cerebritis versus 6 of 20 in the noncerebritis group (0.05 p 0.10).